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Abstract PAI-1 (plasminogen activator inhibitor-1) binds the
urokinase-type plasminogen activator (uPA) and causes its
degradation via its receptor uPAR and low-density lipoprotein
receptor-related protein (LRP). While both uPA and PAI-1 are
chemoattractants, we find that a preformed uPA^PAI-1 complex
has no chemotactic activity and that PAI-1 inhibits uPA-induced
chemotaxis. The inhibitory effect of PAI-1 on uPA-dependent
chemotaxis is reversed when uPAR internalization is inhibited by
the 39 kDa receptor-associated protein or by anti-LRP
antibodies. Under the same conditions, the uPA^PAI-1 complex
is turned into a chemoattractant causing cytoskeleton reorgani-
zation and extracellular-regulated kinase/mitogen-activated pro-
tein kinases activation. Thus, uPAR internalization by PAI-1
regulates cell migration. ß 2001 Published by Elsevier Science
B.V. on behalf of the Federation of European Biochemical So-
cieties.
1. Introduction
Mice lacking urokinase plasminogen activator (uPA) and its
receptor uPAR have a de¢cient migration of various cell
types. The phenotypes of these mice are related to this de¢-
ciency: sensitivity to infections, resistance to aneurisms for-
mation and restenosis, de¢cient muscle regeneration [1^6].
Also plasminogen activator inhibitor type 1 (PAI-1) regulates
cell migration: in fact, PAI-13=3 mice have a de¢cient recruit-
ment of host endothelial cells upon tumor implantation [20].
Moreover, PAI-1 interaction with vitronectin prevents its
binding to integrins modifying cell adhesion and migration
[21^23].
uPA, uPAR and PAI-1 regulate plasmin formation and
¢brin degradation, but also display direct signaling properties
on cell proliferation, adhesion and migration [7^12]. uPA
stimulates migration by uncovering a chemotactic epitope
present at residues 88^92 of uPAR [13] which then cooperates
with a transmembrane adapter to stimulate migration [14].
PAI-1 forms a covalent uPA^PAI-1 complex which inhibits
uPA activity [7] and is rapidly internalized and degraded
[15,16]. This process requires low density lipoprotein recep-
tor-related protein (LRP) and uPAR ([7^19].
Since PAI-1 can induce uPAR internalization, it should also
regulate uPA-dependent migration. We now show that PAI-1
indeed blocks uPA-induced cell migration and that the inhi-
bition is reverted when uPAR and LRP internalization are
blocked.
2. Materials and methods
2.1. Materials
Human ATF was obtained from Jack Henkin (Abbott Park, IL,
USA); human uPA, L. Nolli (BioSearch, Italy); receptor-associated
protein (RAP) and rabbit LRP antiserum by M. Nielsen and A.
Nykjaer (Aarhus, Denmark); rat pro-uPA by S.A. Rabbani (Mon-
treal, QC, Canada). Recombinant PAI-1 is puri¢ed from Escherichia
coli strain BL21[DE3]pLysS transformed with a His-tagged PAI-1
construct (pPAI-HIS), supplied by Dr. R. Gerard (Dallas, TX,
USA). PAI-1 was extracted with lysozyme (0.5 Wg/ml) puri¢ed on
nickel agarose (Qiagen) and heparin Sepharose CL-6B, eluted with
1 M NaCl, 10% glycerol, 50 mM Na2HPO4, pH 6.0 and dialyzed
against phosphate-bu¡ered saline. Recombinant PAI-1 contains 3.3
IU/Wg endotoxin (Lymulus Amoebocyte Lysate Pyrotest, Difco Lab-
oratories, Detroit, MI, USA), i.e. 1.2 IU for 10 nM PAI-1, a concen-
tration that has no biological e¡ect in cell culture. Non-speci¢c rabbit
polyclonal immunoglobulins, non-speci¢c monoclonal IgG1 (MOPC-
21) and formyl-methionyl-leucyl-proline are from Sigma, St. Louis,
MO, USA. Collagen I, ¢bronectin and the secondary FITC-F(ab)
2 fragments of anti-mouse immunoglobulins are from Roche. The
monoclonal anti-phosphorylated extracellular-regulated kinase
(ERK) antibody and the MEK/mitogen-activated protein kinase in-
hibitor PD98059 are from New England Biolabs.
2.2. Immunopuri¢cation of uPA/PAI-1 complexes
Complexes of uPA and recombinant PAI-1 are formed as described
[24] and puri¢ed on uPA antibody AD #394 Protein A Sepharose 4B
column. Fractions are tested on 10% SDS^PAGE.
2.3. Cell culture
Mouse LB6 clone 19 [25] and rat smooth muscle cells (RSMC) [26]
are cultured in Dulbecco’s modi¢ed Eagle’s medium (DMEM) plus
10% fetal calf serum (FCS) while U937 PR9 [27] in RPMI medium
plus 10% FCS. LB6 clone 19 cells express 500 000 human uPAR/cell,
no plasminogen activators or metalloproteases [25,28]. RSMC express
uPAR, uPA and PAI-1 ([26] and data not shown).
2.4. Chemotaxis assays
2.4.1. Cell treatment. Trypsin-detached cells are neutralized with
FCS, washed and resuspended twice in 10 ml serum-free DMEM. The
¢nal pellet is resuspended in 1 ml of serum-free DMEM and cell
concentration determined. U937 PR9 cells are pelleted by centrifuga-
tion, washed thrice in serum-free RPMI, and cell concentration deter-
mined.
2.4.2. Boyden chambers. Chemotaxis is measured in Boyden
chambers as described before [26]. Filters (5 Wm, Corning) are coated
with collagen I. For assays with adherent cells, the ¢lters are further
coated with ¢bronectin [26]. Attractants are added in serum-free me-
dium to the lower chamber. A total volume of 200 Wl serum-free
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DMEM or RPMI is added to the upper chamber, and the cells lay-
ered on top. Inhibitors of migration (i.e. antibodies, RAP) are added
to both lower and upper chambers. 20 000^40 000 cells are allowed to
migrate at 37‡C in 10% CO2 for either 3 (adherent LB6 clone 19,
RSMC) or 1 h (U937 PR9). Experiments are performed in triplicate.
Results are the mean þ S.D. of the number of cells counted in 10 high
power ¢elds per ¢lter. Migration in the absence of chemoattractant is
considered 100%. Data were analyzed with the Student’s t-test, and
values of P6 0.05 are considered signi¢cant.
2.5. Immuno£uorescence microscopy
2.5.1. Cytoskeletal rearrangements. Cells are incubated with ap-
propriate stimulators for 30 min at 37‡C and ¢lamentous actin visu-
alized with TRITC-phalloidin for 30 min at 37‡C and viewed by
conventional immuno£uorescence microscopy as described before
[29].
2.5.2. uPAR internalization. LB6 clone 19 cells are treated with 10
nM uPA plus 500 nM PAI-1 for 1 h at 4‡C and then incubated at
37‡C for 0 or 60 min. uPAR is visualized by immuno£uorescence with
monoclonal antibody R2 followed by recognition with £uoresceinated
anti-mouse FITC IgG as described [24].
2.5.3. Nuclear localization of ERKs. Cells stimulated for 30 min
with 10 nM uPA, 10 nM PAI-1, or 10 nM uPA^PAI-1 complex are
treated with primary anti-phosphorylated ERK antibodies for 24 h at
4‡C, according to the manufacturer’s instructions, and secondary
FITC antibodies. DAPI (4,6-diamidino-2-phenylindole, Roche) is
used to label the nucleus [31].
2.5.4. Cell surface expression of uPAR and LRP. Cyto£uorimetry
is performed as previously described [24].
2.6. Ligand degradation assay
LB6 clone 19 cells, 0.1^0.2U106/2 cm2 well, are incubated with
benzamidine Sepharose 6B-puri¢ed [I125]uPA (2.5^7.5U105 cpm/
nmol) [30] in binding bu¡er (DMEM plus 1 mg/ml bovine serum
albumin, 25 mM HEPES, pH 7.4) for 2 h on ice, as described [19].
Non-bound ligand is eliminated by washing with binding bu¡er, cells
reincubated at 37‡C for 3 h, the medium removed, and trichloro-acetic
acid (TCA) solubility used to quantitate degraded ligand. Cells incu-
bated at 4‡C are used to estimate total binding. Experiments are
performed in triplicate. Results represent the mean þ S.D.
3. Results
3.1. PAI-1 induces chemotaxis
As shown in Fig. 1A, PAI-1 stimulates LB6 clone 19 mi-
gration in a dose-dependent manner reaching a plateau at 2^
20 nM. The e¡ect is not due to an endotoxin contaminant as
its concentration (see Section 2) is too low. Anti-PAI-1 anti-
bodies inhibit PAI-1-, but not fMLP-dependent chemotaxis
(Fig. 1B). This chemotactic activity cannot involve uPA, since
LB6 clone 19 cells do not produce uPA [28].
3.2. PAI-1 inhibits uPA-dependent chemotaxis
Migration of LB6 clone 19 cells is stimulated 2.8-fold by 10
nM uPA, 2.5-fold by 10 nM ATF, the receptor-binding do-
main of uPA, and 2.3-fold by 10 nM PAI-1 (Fig. 2A). The
chemotactic activity of uPA and PAI-1 is not additive since
the [uPA+PAI-1] is not more active than PAI-1 or uPA alone
(Fig. 2A) even at 500 nM PAI-1 (not shown). In contrast, the
combination of 10 nM PAI-1 and ATF, which does not bind
PAI-1, has an additive e¡ect (Fig. 2A). Since PAI-1 and uPA
form a covalent complex, we have tested the activity of a
preformed, puri¢ed uPA^PAI-1 complex. Indeed, unlike free
uPA and PAI-1, the preformed and puri¢ed uPA^PAI-1 com-
plex at the same concentration has no chemotactic e¡ect (Fig.
2B).
Similar results are obtained in suspension-growing U937
PR9 cells. Like in LB6 clone 19 cells, the puri¢ed preformed
uPA^PAI-1 complex has no e¡ect, while free PAI-1 and uPA
induce migration (Fig. 2C). Puri¢ed uPA^PAI-1 complex has
no e¡ect also on RSMC (data not shown) that strongly re-
spond to uPA [26].
The uPA^PAI-1 complex is internalized along with uPAR
and LRP, and degraded [15^17,24]. We have checked that in
LB6 clone 19 cells, that express LRP and uPAR (immuno-
£uorescence and cyto£uorimetric analysis), uPAR is indeed
internalized under the conditions of Fig. 2A (not shown).
We have therefore tested the e¡ect of internalization inhibi-
tors on migration in the presence or absence of the uPA^PAI-
1 complex. The LRP antagonist RAP (Fig. 2B,C) and anti-
LRP antibodies (data not shown) do not or only moderately
(in U937 PR9 cells) a¡ect cell migration. However, in the
presence of RAP the puri¢ed uPA^PAI-1 complex stimulates
chemotaxis of LB6 clone 19 (Fig. 2B) and U937 PR cells (Fig.
2C). Likewise, the uPA^PAI-1 complex has chemotactic ac-
tivity in the presence of anti-LRP antibodies (Fig. 2D).
RAP inhibits [125I]uPA degradation in LB6 clone 19 cells
induced by PAI-1 (Fig. 3A). The TCA solubility of the radio-
active ligand in the incubation medium increases with increas-
Fig. 1. PAI-1 has chemotactic activity in LB6 clone 19 cells.
A: Concentration-dependent stimulation of migration by PAI-1.
B: E¡ect of anti-PAI-1 or unspeci¢c antibodies on PAI-1- or
fMLP-induced migration. The data represent the mean þ S.D. of
two experiments performed in triplicate, with (*) P = 0.015 or
P6 0.001. The value of 100% indicates random (control) migration.
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ing PAI-1 (black bars, a measure of uPA degradation), and
this is inhibited in the presence of RAP (Fig. 3B) or anti-LRP
antibodies (not shown). Thus, under the conditions in which
uPA^PAI-1 acquires chemotactic activity uPA^PAI-1 degra-
dation is blocked.
3.3. PAI-1^uPA complex induces cytoskeleton changes and
nuclear translocation of ERK 1/2 when it is not internalized
Pro-uPA induces cell morphology and cytoskeleton changes
which accompany chemotaxis in RSMC [32]. We have used
phalloidin-FITC £uorescence to show the changes induced by
Fig. 2. PAI-1 inhibits the chemotactic activity of uPA by forming uPA^PAI-1 complexes and causing internalization of uPAR. A: PAI-1 inhib-
its the chemotactic e¡ect of uPA but not of ATF in LB6 clone 19 cells. B: RAP restores the chemotactic activity of preformed, puri¢ed UPA^
PAI-1 complexes in LB6 clone 19 cells. C: The preformed, puri¢ed, uPA^PAI-1 complex has no chemotactic e¡ect in U937 PR9 cells but ac-
quires it in the presence of RAP. D: Anti-LRP antibodies restore the chemotactic activity of preformed uPA^PAI-1 complex on LB6 clone 19
cells. Data are the average from either four (A) or two experiments (B^D); *P6 0.001. The numbers below the abscissa represent the concen-
trations (nM), except for RAP (Wg/ml). For other details, see Section 2 and the legend of Fig. 1.
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uPA on actin cytoskeleton. After 30 min treatment human
pro-uPA, but not puri¢ed uPA^PAI-1 complex, has a pro-
found e¡ect on actin cytoskeleton and cell shape (Fig. 4).
Only in the presence of 5 Wg/ml RAP, which has no e¡ect
on its own, uPA^PAI-1 induces cytoskeletal changes identical
to those observed with pro-uPA. Thus the uPA^PAI-1 com-
plex can cause cytoskeletal rearrangements but only when it
cannot induce internalization of uPAR.
Pro-uPA induces uPAR-dependent phosphorylation and
nuclear localization of ERK 1/2 [31,33,34]. As shown in Fig.
5, a 30 min treatment of RSMC with uPA (30 min), but not
with preformed uPA^PAI-1 complex, induces nuclear staining
with anti-ERK 1/2 antibodies, an e¡ect inhibited by the spe-
ci¢c MEK inhibitor PD98059. Free PAI-1 has no e¡ect as
previously reported [34]. In the presence of RAP, however,
the uPA^PAI-1 complex induces the nuclear translocation of
ERK 1/2. Again, this is inhibited by PD98059, while RAP on
its own has no e¡ect.
4. Discussion
The chemotactic activity of pro-uPA, active uPA and ATF
requires binding to uPAR. Indeed, binding uncovers the che-
motactic epitope present in the linker region between domains
D1 and D2 [13]. Also PAI-1 has migration regulating activity
[22,23,30] but no information is available on the activity of
the uPA^PAl-1 complex.
Even though PAI-1, uPA and ATF stimulate chemotaxis,
the combination of PAI-1 plus uPA is less active than PAI-1
or uPA alone. In contrast, the combination of ATF plus PAI-
1 exerts an additive e¡ect on cell migration (Fig. 2A). ATF
and uPA do not di¡er with respect to the mechanisms by
which they induce migration [13,14,26], both requiring
uPAR, but ATF does not bind PAI-1 and does not induce
uPAR internalization [15,16,24]. The results of Fig. 2, there-
fore, suggest that the inhibitory role of PAI-1 on uPA-depen-
dent migration depends on formation of an uPA^PAI-1 com-
plex, its degradation and the internalization of uPAR and
LRP. Indeed, a puri¢ed, preformed uPA^PAI-1 complex has
no chemotactic activity in LB6 clone 19 or U937 PR9 cells
(Figs. 2 and 3) and does not induce morphological changes in
RSMC (Fig. 5) nor the nuclear translocation of ERK 1/2 (Fig.
5). Under the conditions of our experiments, the puri¢ed
uPA^PAI-1 complex binds uPAR with high a⁄nity, induces
uPAR internalization and is degraded, as expected (Fig. 5,
data not shown and [15,17,24]). However, the block of
uPAR internalization by RAP or LRP antibodies allows
uPA^PAI-1 complex to induce, just like uPA, cell migration
(Figs. 2 and 3), cytoskeleton reorganization (Fig. 4) nor ERK
1/2 nuclear localization (Fig. 5). In these experiments, the
puri¢ed uPA^PAI-1 complex binds uPAR, induces its inter-
nalization and is degraded as expected (Fig. 3 and data not
shown). However, the block of uPAR internalization by RAP
or LRP antibodies allows the uPA^PAl-1 complex to induce,
Fig. 3. In LB6 clone 19 cells, PAI-1-dependent uPA degradation is
prevented in the presence of RAP. A: Cells were incubated at 4‡C
for 2 h with 10 nM [125I]uPA. The amount bound at this time in
the absence of PAI-1 (bound) is taken as 100%. Then, cells are
washed free of ligand, further incubated for 3 h at 37‡C with in-
creasing doses of PAI-1 and the percent of degraded [125I]uPA mea-
sured by evaluating the percent of TCA-soluble radioactivity. The
TCA solubility of the ligand in the absence of cells has been sub-
tracted. Degradation of uPA is expressed as percent of bound uPA.
B: RAP inhibits PAI-1-induced degradation of [125I]uPA. Cells
treated as above were incubated with PAI-1+RAP. In this panel,
uPA degradation obtained with 500 nM PAI-1 was taken as 100%.
(*) P6 0.001 with respect to control.
Fig. 4. A puri¢ed, preformed uPA^PAI-1 complex induces actin cy-
toskeleton reorganization in RSMC but only in the presence of the
internalization inhibitor RAP. Fluorescence microscopy analysis of
sub-con£uent cultures of RSMC treated for 30 min at 37‡C with:
A, none; B, preformed uPA^PAI-1 complex (10 nM); C, uPA^PAI-
1 complex (10 nM) plus 5 Wg/ml RAP; D, pro-uPA (10 nM). Actin
¢laments were stained with TRITC-phalloidin.
C
C
Fig. 5. Nuclear translocation of ERK 1/2 requires the presence of
uPAR on the cell surface. Immuno£uorescence analysis of RSMC
treated for 30 min with the inducers indicated on the left and
stained with antibodies recognizing phosphorylated ERK 1/2 (ERK-
P) or with the nuclear £uorescent probe DAPI. The experiment is
also carried out with cells pre-treated for 1 h with the MEK inhibi-
tor PD98059 (indicated on top). UPA, PAI-1 and the covalent,
puri¢ed uPA^PAI-1 complex are used at 10 nM. RAP is used at
5 Wg/ml.
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just like uPA, cell migration (Figs. 2 and 3). Thus, inhibitors
of uPAR internalization turn the inactive uPA^PAI-1 com-
plex into a stimulator of cell migration in three di¡erent cell
lines, RSMC, LB6 clone 19 and U937 cells. Since PAI-1 on its
own does not induce ERK 1/2 phosphorylation and translo-
cation (Fig. 5) [34], the lack of signaling is likely due to a
combination of uPAR internalization and/or ligand degrada-
tion.
Several reports indicate that uPAR internalization via LRP
plays a key role in signal transduction and regulation of cell
migration. For example, RAP-treated MCF-7 cells or LRP-
de¢cient cells display an increase in both cell surface uPAR
and cell migration [35,36]. The e¡ect of PAI-1 can be exerted
not only through LRP, but also through VLDL-R, which also
binds RAP and can cause uPAR internalization [19]. Indeed,
neutralization of the VLDL-R with RAP decreases uPAR
catabolism and increases cell migration [36]. Thus PAI-1 is
an important regulator of cell migration.
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